Please login to the form below

Not currently logged in
Email:
Password:

liver transplant

This page shows the latest liver transplant news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Intercept's rare liver disease drug

CHMP backs Intercept's rare liver disease drug

CHMP backs Intercept's rare liver disease drug. Ocaliva on track for EU approval as analysts predict blockbuster sales. ... While a rare disease, PBC is one of the most common causes of a liver transplant among women in Europe, according to David Jones,

Latest news

  • FDA panel backs Intercept's rare liver disease drug FDA panel backs Intercept's rare liver disease drug

    FDA panel backs Intercept's rare liver disease drug. Ocaliva recommended for accelerated approval as a primary biliary cholangitis treatment. ... will result in liver failure and death unless patients can get a liver transplant.

  • Harvoni cleared for broader use in hepatitis C Harvoni cleared for broader use in hepatitis C

    Harvoni cleared for broader use in hepatitis C. Gilead Sciences’ drug wins US approval for use in liver transplant patients. ... for GT 1-infected patients with decompensated cirrhosis, including those who have received a liver transplant.

  • Access to new hep C treatments put under the spotlight Access to new hep C treatments put under the spotlight

    Those who are living with serious liver damage need rapid, tolerable and effective treatment to prevent further progression of their disease. ... This works out at a much lower cost than the £50, 000-£70, 000 it costs for a liver transplant in these

  • NHS England sets up new £190m hep C fund NHS England sets up new £190m hep C fund

    The money will go to the roughly 3, 500 hepatitis C patients in England and Wales with cirrhosis of the liver, and will gain access by the end of this year ... This is why there have been smaller silo funds being used to help those most at risk of

  • Silver lining as Shire rare disease programme hits a setback Silver lining as Shire rare disease programme hits a setback

    It is characterised by liver damage and heart problems and while life expectancy is variable up to a third of patients will eventually need a liver transplant. ... by accumulation of fat in liver cells and inflammation in the liver, later this year.

More from news
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    NASH and biosimilars. One therapeutic indication that could be seen to be gaining much attention was NASH, which is the fastest growing cause of liver cancer and liver transplant in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics